eXagen™ is developing quantitative polymerase chain reaction (qPCR) assays that assess messenger ribonucleic acids (mRNAs) in peripheral blood mononuclear cells linked to inflammatory bowel disease. The eXagen test will assist health care providers in differentiating patients with inflammatory bowel disease from those with irritable bowel syndrome. A second diagnostic assay will help distinguish between Crohn's Disease and Ulcerative Colitis in patients with inflammatory bowel disease. The diagnosis of inflammatory bowel disease currently relies on a range of diagnostic procedures. New laboratory assays that can contribute to the diagnosis of inflammatory bowel disease will be of value.